Analyzing Heart Uptake of Bone Medications in Patients with Cardiac Amyloidosis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the myocardial uptake of bone-seeking radiopharmaceuticals in patients diagnosed with cardiac transthyretin amyloidosis (ATTR). It aims to include 35 patients who have a suspected diagnosis of cardiac ATTR and will undergo cardiac planar radionuclide imaging as part of their routine care. The study focuses on developing quantitative methods for diagnosis, prognosis assessment, and evaluating therapeutic responses to treatments like tafamidis meglumine, which has shown promise in reducing mortality and hospitalizations. By utilizing advanced imaging techniques, the study seeks to enhance the understanding and management of this condition.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Medical history of Heart Failure (HF) with at least 1 prior hospitalization for HF or clinical evidence of HF (without hospitalization) manifested by signs or symptoms of volume overload or elevated intracardiac pressures that required/requires treatment with a diuretic for improvement, and an increase of BNP \>200 pg/mL and/or NT-proBNP \>500 pg/mL
* Suspected cardiac ATTR amyloidosis
* Evidence of cardiac involvement by echocardiography with an end-diastolic interventricular septal wall thickness \> 12 mm
* Patient signed consent
* Contraception method

Exclusion Criteria:

* New York Heart Association (NYHA) functional class IV despite diuretic treatment
* Life expectancy \<6 month due to the severity of cardiac amyloidosis and/or comorbidities
* Aortic valve surgical or percutaneous replacement within 30 days or planned within months
* Presence of primary (light chain) amyloidosis
* Contraindication to tafamidis
* Pregnancy and breast feeding ; pregnancy test in women of reproductive age irrespective of contraception method)
* Adults with protective measures

Where it's running

• CHU de Caen
  Caen, France Recruiting
• Clinique du Bois
  Lille, France Recruiting

Study contacts

• Study coordinator: Damien Legallois, MD
• Email: damien.legallois@unicaen.fr
• Phone: 33230165709

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Using tiny blood particles to detect and track ATTR heart amyloidosis

  This project will test whether tiny blood particles called extracellular vesicles can help detect and track transthyretin (ATTR) amyloid cardiomyopathy in people with or at risk for ATTR.

  Recruiting University of Sao Paulo General Hospital · São Paulo, São Paulo · NCT07314268

• Acoramidis for ATTR-CM: Cardiac Imaging Study

  This study tests whether acoramidis can improve heart structure and function in people with transthyretin amyloid cardiomyopathy.

  Recruiting Phase 4 Eidos Therapeutics, a BridgeBio company · St Louis, Missouri · NCT07695701

• Long-term safety of eplontersen in adults with transthyretin amyloidosis, including those with prior liver transplant or severe liver impairment

  This study will see if eplontersen remains safe over time for adults with transthyretin amyloidosis, including people who have had a liver transplant or have severe liver problems.

  Recruiting at 6 sites AstraZeneca · Los Angeles, California and 5 other locations · NCT07654855

• Annular ligament biopsy during endoscopic carpal tunnel surgery to screen for transthyretin amyloidosis

  This study tests whether a biopsy of the annular ligament during carpal tunnel surgery can reliably indicate transthyretin amyloidosis and match the results of the standard synovial biopsy.

  Recruiting Clinique Saint Jean, France · Montpellier · NCT07644325

• Eplontersen exposure during pregnancy and breastfeeding: outcomes

  This project collects reports to see if exposure to eplontersen during pregnancy or breastfeeding affects mothers, fetuses, or infants with transthyretin amyloidosis.

  Recruiting AstraZeneca · Frankfurt · NCT07205666

• Preventing transthyretin amyloidosis in young carriers of a genetic variant

  This study is testing if a medication called acoramidis can help prevent transthyretin amyloidosis in young adults who carry a specific genetic variant that puts them at risk for the disease.

  Recruiting at 104 sites Phase 3 Eidos Therapeutics, a BridgeBio company · La Jolla, California and 103 other locations · NCT06563895

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.